Science & Technology Review
|
2021, 39(7): 38-47
• Exclusive: Tumor Markers •
Advances in research of POLE/POLD1 mutations in cancer immunotherapy
Full
MAI Zongjiong, PU Hengying, WANG Feng
Affiliations
Department of Medical Oncology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China
Published: 2021-04-13
doi: 10.3981/j.issn.1000-7857.2021.07.004
Outline
This article expounds the involvement of subunits encoded by DNA polymerase (POLE) and DNA polymerase delta 1 (POLD1) in DNA replication and proofreading, summarizes the effects of POLE/POLD1 mutations on tumor mutation load and intratumoral immune cell infiltration, and reviews the research progress of POLE/POLD1 mutations in immunotherapy of endometrial cancer, colorectal cancer and lung cancer. This article also discusses the challenges faced by POLE/POLD1 mutations as potential molecular markers for the predicting efficacy of immune checkpoint inhibitors.
POLE
/
POLD1
/
mutation
/
immunotherapy
/
biomarker
MAI Zongjiong, PU Hengying, WANG Feng.
Advances in research of POLE/POLD1 mutations in cancer immunotherapy[J].
Science & Technology Review,
2021
, 39
(7)
: 38
-47
.
DOI: 10.3981/j.issn.1000-7857.2021.07.004
Year 2021 volume 39 Issue 7
PDF
2502
1782
Cite this Article
BibTeX
Article Info
doi: 10.3981/j.issn.1000-7857.2021.07.004
- Receive Date:2020-07-21
- Online Date:2021-05-13
- Published:2021-04-13